Publications by authors named "Dorien van der Biessen-van Beek"
Article Synopsis
- Testicular cancer survivors (TCS) who received platinum-based chemotherapy are at a higher risk for developing colorectal cancer (CRC) compared to average-risk individuals.
- A study involving TCS from four Dutch hospitals found that 8.7% of them had advanced neoplasia, significantly higher than the 1.7% found in matched controls.
- The results indicate that TCS have a greater prevalence of colorectal neoplasia and advanced neoplasia, suggesting that colonoscopy screenings may be beneficial for this group; further cost-effectiveness studies are needed to determine the best screening practices.
Colorectal cancer surveillance (CCS) with colonoscopy every five years is advised for Hamartoma Tumour Syndrome (PHTS) patients aged ≥40 due to an increased colorectal cancer (CRC) risk. However, data to support CCS guidelines are scarce and available CRC risks are low (0-5% at age 50) and likely overestimated. We aimed to assess the detection and yield of CCS for PHTS patients without a CRC history.
View Article and Find Full Text PDFDiagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study.
Berbel L M Ykema Tanya M Bisseling Manon C W Spaander Leon M G Moons Dorien van der Biessen-van Beek
BMC Gastroenterol
February 2021
Background: Testicular cancer (TC) survivors have an increased risk of various second primary malignancies. A recent cohort study detected an increased risk of colorectal cancer (CRC) in TC survivors treated with platinum-based chemotherapy with a hazard ratio of 3.9.
View Article and Find Full Text PDF